CD4 and melanoma: The mechanism underlying this expansion of Tregs may be similar to that previously described in human breast and ovarian cancer46 47 and the B16 mouse model of melanoma.30 In those studies, tolerogenic pDCs engaged ICOS on CD4 T cells, thereby promoting differentiation to Tregs, and causing immunosuppression in tumors.